The Safety Nucleus: From Compliance to Strategic Enabler

The Safety Nucleus: From Compliance to Strategic Enabler

Ipsen’s Pav Rishiraj joins David Kološić to discuss why pharmacovigilance is the nucleus of the industry, and how moving from reactive to predictive safety will improve benefit-risk analysis and establish safety as a strategic enabler for the entire business.

Humanizing PV: Better Patient Experience, Better Safety Data

In this episode of Safety [R]Evolution, Andrew Rut joins David Kološić to discuss shifting PV from reactive data collection and reporting to a predictive, digital-first model that carefully considers the patient experience, integrates AI and automation, and positions safety as a competitive advantage.

Bringing Safety Operations and Science Together: Big Bang Approach

UCB’s Adrian Maynier and Veeva’s Mayuran Croos join David Kološić to discuss how to approach a “big bang” consolidation of 17 siloed safety systems into one unified platform for case processing, reporting, signal detection, and content.

Building a Connected Safety Platform for the Future

David Kološić speaks with Veeva’s Marius Mortensen about the long-term vision for Veeva Safety; the benefits of starting with a trusted, validated cloud platform; and how a platform approach enables connected data and processes, advanced automation, and AI.

Strengthening Safety Oversight for CRO-Sponsor Partnerships

Biomapas’ Martijn van de Leur and Olga Asimaki join David Kološić to discuss the importance of CRO-sponsor partnerships in pharmacovigilance. They also talk about the need for simplification and standardization, progress on automation and AI, and how QPPV’s are adapting to shifting technology.